Cannabis Law Report

DECEMBER 6, 2022

Cannabinoid receptors are currently the most popular targets for CNS in preclinical development, with 391 drugs tagged in total. In 2022, a surge in the pipeline has led […].

Cannabinoids 52

Cannabinoids Pharmaceutical Treatment Law 52

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. GW Pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Medical Marijuana Program Connection

OCTOBER 6, 2023

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) (“Anebulo”), today announced. Read More

Pharmaceutical 64

Pharmaceutical Cannabinoids Business 64

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

MARCH 26, 2022

Jazz Pharmaceuticals is investing £75m in a plant based at Kent Science Park (KSP) in Sittingbourne, Kent. ” ‘Strategic investment’ Jazz Pharmaceuticals currently manufactures the extract, active pharmaceutical ingredients and the formulated drug products at KSP, occupying 12 buildings with more than 400 employees.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Veriheal

AUGUST 12, 2021

million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). This, the authors say, “is well below the dose commonly associated with pharmaceutical products (e.g. CBD, which constitutes a $2,770.8

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

Cannabis Law Report

APRIL 22, 2021

Patent protects Supera-CBD, a preclinical cannabidiol derivative that targets cannabinoid receptor type 2 for the treatment of neuroinflammatory and neurodegenerative… Read More.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment CBD 98

Cannabis Law Report

DECEMBER 10, 2022

BusinessCann reports Oxford Cannabinoid Technologies (OCT) has seen its share price jump by more than 20% this week after announcing that its CEO Dr John Lucas would be stepping down. The pharmaceutical company announced on Monday, December 5 that Dr Lucas would leave the company by the end of the year, staying on until then […].

Cannabinoids 52

Cannabinoids Pharmaceutical Compliance Compliance 52

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Medical Marijuana Program Connection

FEBRUARY 10, 2023

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid. Read More

Pharmaceutical 40

Pharmaceutical Cannabinoids Business 40

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Project CBD

JULY 28, 2023

Project CBD: Your presentation with Allyn Howlett at the International Cannabinoid Research Society conference in Toronto (June 2023) discussed the chemical conversion of CBD into Δ8-THC (delta-8 THC) and “numerous additional THC isomers. At issue are potent, intoxicating cannabinoids other than cannabis-derived Δ9-THC.

THC 212

THC Cannabinoids Hemp Research and Development 212

Kind Meds (Cannabis Education Blog)

JANUARY 27, 2022

Lately, the cannabinoid CBN (or cannabinol) has been rising in popularity. CBN is a cannabinoid that can be synthesized out of THC. Cannabinol – more commonly known as CBN – is one of over one hundred cannabinoids found in the cannabis plant. The CBN cannabinoid begins to form when THC is oxidized. What Is CBN?

Cannabinoids 52

Cannabinoids Treatment Extraction THC 52

Cannabis Law Report

SEPTEMBER 17, 2021

Patent 16/424,351, a Cannabinoid Composition and Method of Sublingual, Buccal, and Oral Mucosa Delivery. This patent focuses on a formulation that includes a cannabinoid extract that is pharmaceutically effective by systemic delivery to the recipient’s oral mucosal lining. is a women-led cannabinoid health science company.

Cannabinoids 52

Cannabinoids Pharmaceutical Digestion Terpenes 52

Cannabis Law Report

DECEMBER 3, 2020

3, 2020 /PRNewswire/ — Pure Jamaican Limited , provider of pharmaceutical cannabinoids, genetics and consumer packaged goods products in large volumes for … Read More. MIAMI , Dec.

Pharmaceutical 64

Pharmaceutical Legislation Packaging Cannabinoids 64

Cannabis Law Report

OCTOBER 5, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). Accelerated timelines to clinical trials and expansion of drug development pipeline.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 20, 2022

Proactive Research analyst Ed Stacey presents his analysis on Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialising in drug development from cannabinoids (compounds derived from cannabis).

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical Medicine 52

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. Pre-Close Trading Update; US OTC QB Market Application. & & Notice of 2021 Final Results. . Details of a presentation to investors via the InvestorMeet Platform will be announced shortly. Since the year-end, the £2.6

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

AUGUST 9, 2021

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Cannabis Law Report

NOVEMBER 13, 2021

A cardiologist with no public comments on cannabinoid therapies, Dr. Robert Califf, has been nominated to take over as commissioner of the U.S. Califf has said nothing publicly about cannabinoids such as CBD. Hemp Today reports. Food and Drug Administration. More at [link].

Cannabinoids 52

Cannabinoids Therapy Pharmaceutical Hemp 52

Cannabis Law Report

JULY 28, 2021

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Project CBD

FEBRUARY 1, 2023

Anyone who has paid any attention to the cannabis “wellness” industry in recent years — whether through state medical and recreational programs or the free-for-all national CBD market — will be familiar with cannabinoid-infused topicals marketed to treat minor aches and pains.

Conditions 130

Conditions THC CBD Cannabinoids 130

Cannabis Law Report

SEPTEMBER 8, 2021

The mission of the United Cannabis Business Association is to establish a comprehensive, statewide cannabinoid policy. Comprehensive cannabinoid policy provides for fair and equal regulation of all cannabinoids, regardless of their source or how they were derived.

Cannabinoids 95

Cannabinoids Policy Advocacy Hemp 95

Cannabis Life Network

MAY 5, 2019

The acquisition brings together Canopy Growth‘s medical business with Europe’s largest cannabinoid-based pharmaceuticals company. C3 is a leading manufacturer and distributor of dronabinol, a registered pharmaceutical drug in Germany, Austria, Switzerland, and Denmark.

Cannabinoids 44

Cannabinoids Pharmaceutical Patients Business 44

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

OCTOBER 27, 2021

a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has successfully completed commercial-scale, fermentation-based production campaigns for its Lygos CBx cannabinoid products, including CBG (cannabigerol), CBC (cannabichromene), CBD (cannabidiol), and CBDA (cannabidiolic acid).

Cannabinoids 52

Cannabinoids Pharmaceutical Agriculture CBD 52

Cannabis Law Report

JANUARY 12, 2021

IRISYS, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that it was awarded… Read More.

Treatment 59

Treatment Cannabinoids Pharmaceutical Law 59

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

SpeedWeed

JULY 29, 2021

In addition to THC and CBD, hemp and cannabis contain dozens of other cannabinoids that can aid everything from appetite suppression and weight loss to fighting insomnia or inflammation. This amazing cannabinoid is THCV (tetrahydrocannabivarin). . This rare cannabinoid is formed when THC degrades due to age or heat.

Sleep 52

Sleep Cannabinoids Oil THC 52

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

SpeedWeed

MAY 10, 2021

If you or a loved one suffer from depression, rare cannabinoid CBC (cannabichromene) may offer hope for a happier future. The third most prevalent cannabinoid in hemp and cannabis, CBC’s mood-elevating properties are about ten times more effective than CBD, making it a promising cannabinoid for reducing stress.

Cannabinoids 52

Cannabinoids Terpenes Tincture Oil 52